Zoptarelin doxorubicin

Drug Profile

Zoptarelin doxorubicin

Alternative Names: AEZS-108; AN-152; D-81858; Doxorubicin-GnRH agonist conjugate; ZEN-008; Zoptrex

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc; National Cancer Institute (USA); University of Southern California
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Endometrial cancer

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Ovarian cancer; Prostate cancer; Urogenital cancer

Most Recent Events

  • 08 May 2017 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 08 May 2017 Discontinued - Phase-II for Breast cancer (Metastatic disease, Second-line therapy or greater) in Germany (IV)
  • 08 May 2017 Discontinued - Phase-II for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top